Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373752 | 0.86 | KDM4E (1.00) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL2035848 | 0.85 | KDM4E (0.76) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL2031887 | 0.84 | KDM4E (0.74) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL2031582 | 0.84 | KDM4E (0.74) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL5376798 | 0.84 | CHEK1 (1.00) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL5372352 | 0.84 | KMT2A (0.72) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL13665414 | 0.84 | KMT2A (0.72) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL5375281 | 0.84 | KDM4E (0.72) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL5382593 | 0.83 | MEN1 (0.71) | KMT2AMEN1POLBKDM4ECHEK1 | |
| SCHEMBL4298475 | 0.83 | MEN1 (0.71) | KMT2AMEN1POLBKDM4ECHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202244-B2 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202244-B2 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202244-B2 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040014765-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003101444-A1 | DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014765-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | KMT2A 1919/4885MEN1 1973/4885POLB 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.